Financial News

NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side

STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that its Chief Executive Officer and Co-Founder Alex Zwyer is scheduled to present a corporate overview and meet with investors at The Micro Cap Rodeo Fall Harvest Conference to be held virtually October 5-8, 2021.

Event Details:

Date: October 5, 2021
Time: 9:00am ET

Event Access: Please click this link to access the NLS presentation. A replay will also be available on Company's website at https://nls-pharma.com/

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS has recently initiated a phase 2 study in the U.S. evaluating Quilience® in adult subjects suffering from Narcolepsy. Previously, NLS successfully completed a phase 2 study in the U.S. evaluating Nolazol® (mazindol controlled-release) in adult subjects suffering from ADHD. The study met all primary and secondary endpoints and Nolazol® was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Up to 1/3rd of narcoleptic patients are also diagnosed with ADHD.

Corporate contact

Alex Zwyer, CEO: +41 41 618 80 00

Investor Relations contact

Cindy Rizzo: +1 908-229-7050

www.nlspharma.com

SOURCE: NLS Pharmaceutics AG



View source version on accesswire.com:
https://www.accesswire.com/666124/NLS-Pharmaceutics-to-Participate-in-The-Micro-Cap-Rodeo-Fall-Harvest-Conference-Best-Ideas-from-the-Buy-side

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback